Research shows that treatment with atypical antipsychotics appears to significantly increase the risk of mortality and severe adverse events among patients with Parkinson’s disease psychosis (PDP), when compared to patients with PDP who did not receive antipsychotics.
A recent study showed that retinal abnormalities detected through objective electrophysiological measurements may help identify the pathogenesis of major depressive disorder and possibly other psychological conditions.
Alemtuzumab is an effective strategy to prevent relapses and other disease activity associated with multiple sclerosis (MS), according to Heinz Wiendl, MD, a professor at the University of the University of Münster. The research will be explained in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.
The use of filtered sunlight is both safe and noninferior to conventional phototherapy for the treatment of neonatal hyperbilirubinemia. This is important because severe neonatal hyperbilirubinemia can lead to fatal complications, and because in some cases, existing guidelines for managing neonatal hyperbilirubinemia explicitly discourage the use of sunlight for the treatment.
Race and vitamin D levels may play a crucial role in the risk of multiple sclerosis (MS), according to Annette M. Langer-Gould, MD, PhD, of Kaiser Permanente in Pasadena, California. The findings are set to be presented in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.
Rhodiola rosea (R. rosea), also known as roseroot, may be an effective antidepressant that is safer and better tolerated than sertraline.
Japanese regulators have approved AbbVie's Viekirax to treat patients with genotype 1 chronic hepatitis C, including those with compensated cirrhosis, the most common type of hepatitis in that country.
Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia features once-monthly and six-week dosing options.
California's Gov. Jerry Brown signed a controversial law permitting physicians to prescribe lethal doses of drugs in cases where a patient has six months or less to live.